Any Dkt No. PL08146.107 USSN: 08/844,215 PATENT

4F (SEQ ID NO:26) or a degenerate variant thereof; and the contiguous sequence of nucleotides depicted in Figure 4G (SEQ ID NO:27) or a degenerate variant thereof; and

a second nucleotide sequence encoding a second polypeptide that is a binding portion of a  $\kappa$  light chain variable region ( $V_L$ ) of said human Fab molecule where said light chain variable region exhibits immunological binding affinity for a hepatitis C virus (HCV) E2 antigen, and wherein the second nucleotide sequence is selected from the group consisting of the contiguous sequence of nucleotides depicted in Figure 3A (SEQ ID NO:15) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3B (SEQ ID NO:16) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3C (SEQ ID NO:17) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3D (SEQ ID NO:18) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3E (SEQ ID NO:19) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3F (SEQ ID NO:20) or a degenerate variant thereof; and the contiguous sequence of nucleotides depicted in Figure 3G (SEQ ID NO:21) or a degenerate variant thereof, and wherein said Fab molecules have binding affinity greater than 1 x  $10^7$  M<sup>-1</sup> for HCV E2.

48. (Three times amended) An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a γ1 heavy chain variable region (V<sub>H</sub>) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than 1 x 10<sup>7</sup> M<sup>-1</sup> for a hepatitis C virus (HCV) E2 antigen and further wherein the first nucleotide sequence is selected from the group consisting of the contiguous sequence of nucleotides depicted in Figure 4A (SEQ ID NO:22) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 4B (SEQ ID NO:23) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 4C (SEQ ID NO:24) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 4D (SEQ ID NO:25) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 4D (SEQ ID NO:25) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 4E (SEQ ID NO:19) or a degenerate variant thereof; the contiguous

Atty Dkt No. PL08146.107 USSN: 08/844,215 PATENT

sequence of nucleotides depicted in Figure 4F (SEQ ID NO:26) or a degenerate variant thereof; and the contiguous sequence of nucleotides depicted in Figure 4G (SEQ ID NO:27) or a degenerate variant thereof.

56. (Three times amended) An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a κ light chain variable region (V<sub>L</sub>) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than 1 x 10<sup>7</sup> M<sup>-1</sup> for a hepatitis C virus (HCV) E2 antigen and further wherein the first nucleotide sequence is selected from the group consisting of the contiguous sequence of nucleotides depicted in Figure 3A (SEQ ID NO:15) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3B (SEQ ID NO:16) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3C (SEQ ID NO:17) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3D (SEQ ID NO:18) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3E (SEQ ID NO:19) or a degenerate variant thereof; the contiguous sequence of nucleotides depicted in Figure 3F (SEQ ID NO:20) or a degenerate variant thereof; and the contiguous sequence of nucleotides depicted in Figure 3G (SEQ ID NO:21) or a degenerate variant thereof.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."